Carol Ann Satler

WORK HISTORY

EDUCATION

ABOUT CAROL ANN SATLER

I am a physician executive and biopharmaceutical leader with over 20 years of experience guiding R&D, clinical development, and medical affairs across leading global organizations including Pfizer, Sanofi, Gilead, and Bayer. I have built and led high-performing global teams of 300+ professionals and managed portfolios spanning respiratory, fibrosis, cardiovascular, metabolic, renal, rare diseases, and hematology-oncology.Throughout my career, I have delivered results across the full spectrum of drug discovery, development, and commercialization—successfully overseeing NDA/MAA submissions, global regulatory interactions, and multiple product launches that achieved blockbuster status. My leadership has contributed to approvals and commercial success for products such as Lipitor, Norvasc, Adempas, Velcade, Lovenox, Tikosyn, and Plavix, generating multi-billion-dollar global revenues.A strategic and trusted executive, I bring a unique combination of scientific depth, business acumen, and operational excellence. I have led programs integrating AI-driven small molecule discovery, gene therapy, biologics, and combination products, and managed global clinical and medical operations across the U.S, Europe, Japan, and China. My experience extends to business development, investor relations, and board advisory roles for emerging biotechnology companies, helping to shape portfolios and guide growth strategies.Recognized for aligning cutting-edge science and technology with clinical and commercial strategy, I thrive in dynamic, high-growth environments where innovation meets execution. I am passionate about building organizations that deliver transformative therapies and measurable value to patients, partners, and shareholders alike.Career Highlights:Directed development and FDA/EMA approval of multiple cardiovascular and respiratory assetsAdvanced drug discovery at Gilead, identifying and championing assetsSpearheaded U.S, EU, and Japan commercialization for Sanofi’s Plavix, driving sales growth from $8B annually.Board Member for Carbon Biosciences and ViCardia Therapeutics, providing oversight on gene therapy and mitochondrial drug development programs.Harvard-trained and board-certified, I am dedicated to advancing the next generation of therapies that redefine standards of care and improve global health outcomes.